A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population

Bruce Lee, Anna K. Ercius, Kenneth J. Smith

Research output: Contribution to journalArticle

Abstract

Immunosenescence decreases influenza vaccine efficacy in older adults (age 65 and over). Strategies such as vaccine adjuvants are being developed to overcome immunosenescence. Our computer simulation model represented the decision to give an older adult either standard influenza vaccine or adjuvanted influenza vaccine and found the adjuvanted vaccine to be dominant in many scenarios, resulting in lowered cost and greater effectiveness. An adjuvanted vaccine that is 100% effective in overcoming immunosenescence remained dominant until its cost exceeded the standard vaccine cost by $65. In a single influenza season, the adjuvant would prevent 496,533 influenza cases, 171,981 hospitalizations, and 70,429 deaths.

Original languageEnglish (US)
Pages (from-to)2251-2257
Number of pages7
JournalVaccine
Volume27
Issue number16
DOIs
StatePublished - Apr 6 2009
Externally publishedYes

Fingerprint

Economic Models
vaccine adjuvants
Influenza Vaccines
economic impact
influenza
Vaccines
vaccines
Computer Simulation
Human Influenza
Population
Costs and Cost Analysis
Cost-Benefit Analysis
Hospitalization
computer simulation
adjuvants
simulation models
death
Immunosenescence

Keywords

  • Computer simulation
  • Influenza vaccine adjuvant
  • Older adults

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population. / Lee, Bruce; Ercius, Anna K.; Smith, Kenneth J.

In: Vaccine, Vol. 27, No. 16, 06.04.2009, p. 2251-2257.

Research output: Contribution to journalArticle

@article{15b058e7c1db4a87a6659f187e9c5162,
title = "A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population",
abstract = "Immunosenescence decreases influenza vaccine efficacy in older adults (age 65 and over). Strategies such as vaccine adjuvants are being developed to overcome immunosenescence. Our computer simulation model represented the decision to give an older adult either standard influenza vaccine or adjuvanted influenza vaccine and found the adjuvanted vaccine to be dominant in many scenarios, resulting in lowered cost and greater effectiveness. An adjuvanted vaccine that is 100{\%} effective in overcoming immunosenescence remained dominant until its cost exceeded the standard vaccine cost by $65. In a single influenza season, the adjuvant would prevent 496,533 influenza cases, 171,981 hospitalizations, and 70,429 deaths.",
keywords = "Computer simulation, Influenza vaccine adjuvant, Older adults",
author = "Bruce Lee and Ercius, {Anna K.} and Smith, {Kenneth J.}",
year = "2009",
month = "4",
day = "6",
doi = "10.1016/j.vaccine.2009.02.024",
language = "English (US)",
volume = "27",
pages = "2251--2257",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "16",

}

TY - JOUR

T1 - A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population

AU - Lee, Bruce

AU - Ercius, Anna K.

AU - Smith, Kenneth J.

PY - 2009/4/6

Y1 - 2009/4/6

N2 - Immunosenescence decreases influenza vaccine efficacy in older adults (age 65 and over). Strategies such as vaccine adjuvants are being developed to overcome immunosenescence. Our computer simulation model represented the decision to give an older adult either standard influenza vaccine or adjuvanted influenza vaccine and found the adjuvanted vaccine to be dominant in many scenarios, resulting in lowered cost and greater effectiveness. An adjuvanted vaccine that is 100% effective in overcoming immunosenescence remained dominant until its cost exceeded the standard vaccine cost by $65. In a single influenza season, the adjuvant would prevent 496,533 influenza cases, 171,981 hospitalizations, and 70,429 deaths.

AB - Immunosenescence decreases influenza vaccine efficacy in older adults (age 65 and over). Strategies such as vaccine adjuvants are being developed to overcome immunosenescence. Our computer simulation model represented the decision to give an older adult either standard influenza vaccine or adjuvanted influenza vaccine and found the adjuvanted vaccine to be dominant in many scenarios, resulting in lowered cost and greater effectiveness. An adjuvanted vaccine that is 100% effective in overcoming immunosenescence remained dominant until its cost exceeded the standard vaccine cost by $65. In a single influenza season, the adjuvant would prevent 496,533 influenza cases, 171,981 hospitalizations, and 70,429 deaths.

KW - Computer simulation

KW - Influenza vaccine adjuvant

KW - Older adults

UR - http://www.scopus.com/inward/record.url?scp=61849122853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61849122853&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.02.024

DO - 10.1016/j.vaccine.2009.02.024

M3 - Article

C2 - 19428839

AN - SCOPUS:61849122853

VL - 27

SP - 2251

EP - 2257

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 16

ER -